Katrien De Bock
Prof. Dr. at ETH Zürich
Research Interests
Explore related searches
Contact this professor
Recent Grants
Grant: Close
Endothelial metabolism to promote muscle revascularization and regeneration
Open Date: 2022-04-01
Close Date: 2026-03-31
Articles (16)
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma
Metastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted therapy treatments, such as MAPK inhibitors (MAPKi). A leading cause of resistance to targeted therapy is a dynamic transition of melanoma cells from a proliferative to a highly invasive state, a phenomenon called phenotype switching. Mechanisms regulating phenotype switching represent potential targets for improving treatment of patients with melanoma. Using a drug screen targeting chromatin regulators in patient-derived three-dimensional MAPKi-resistant melanoma cell cultures, we discovered that PARP inhibitors (PARPi) restore sensitivity to MAPKis, independent of DNA damage repair pathways. Integrated transcriptomic, proteomic, and epigenomic analyses demonstrated that PARPis induce lysosomal autophagic cell death, accompanied by enhanced mitochondrial lipid metabolism that ultimately increases antigen presentation and sensitivity to T-cell cytotoxicity. Moreover, transcriptomic and epigenetic rearrangements induced by PARP inhibition reversed epithelial–mesenchymal transition-like phenotype switching, which redirected melanoma cells toward a proliferative and MAPKi-sensitive state. The combination of PARP and MAPKis synergistically induced cancer cell death both in vitro and in vivo in patient-derived xenograft models. Therefore, this study provides a scientific rationale for treating patients with melanoma with PARPis in combination with MAPKis to abrogate acquired therapy resistance. Significance: PARP inhibitors can overcome resistance to MAPK inhibitors by activating autophagic cell death and reversing phenotype switching, suggesting that this synergistic combination could help improve the prognosis of patients with melanoma.
Year:
2023
Collaborators (17)
Eling D. de Bruin
ETH Zürich
Andrés A Urrutia
Universidad Autónoma de Madrid
Christoffer Clemmensen
Københavns Universitet
Mark Larance
Senior Lecturer
University of Sydney
Olivier Braissant
-
Jakob G Knudsen
Assistant professor
University of Copenhagen
Nicoline Resen Andersen
Københavns Universitet
Joachim Fandrey
Universitätsprofessor
Universität zu Köln Medizinische Fakultät
Ekaterina Khatchatourova
University of Bern
Peter Carmeliet
Aarhus University
Erik A. Richter
Københavns Universitet
Christian Stockmann
-
Laura Hinte
ETH Zürich
Christophe Delecluse
Full professor
KU Leuven
Michael O. Hottiger
University of Zurich
Daniel Castellano-Castillo
Assistant Professor
University of Malaga
Francisco Javier Ruiz Ojeda
Universidad de Granada

How do I reach out?
Sign in for free to see their profile details and contact information.